XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.

XM Amerika Qoʻshma Shtatlari fuqarolariga xizmat koʻrsatmaydi.
B
B

BectonDickinson

Yangiliklar

Reuters - 2 kun oldin

Becton Dickinson agrees to settle about 38,000 hernia mesh suits

Becton Dickinson agrees to settle about 38,000 hernia mesh suits By Brendan Pierson Oct 3 (Reuters) - Becton Dickinson BDX.N has agreed to resolve nearly all U.S. lawsuits by people who say they were injured by its hernia repair mesh, about 38,000 cases, in an unusual settlement overseen jointly by state and federal courts, promising an end to litigation stretching back almost two decades.
B
Reuters - 3 kun oldin

Becton Dickinson And Co Reaches Agreement To Resolve Vast Majority Of Hernia Litigation

BRIEF-Becton Dickinson And Co Reaches Agreement To Resolve Vast Majority Of Hernia Litigation Oct 2 (Reuters) - Becton Dickinson and Co BDX.N : BD REACHES AGREEMENT TO RESOLVE VAST MAJORITY OF HERNIA LITIGATION BD - SETTLEMENT AMOUNT WITHIN CURRENT PRODUCT LITIGATION RESERVE AND WILL BE PAID OUT OVER A MULTI-YEAR PERIOD BD - SETTLEMENT WILL NOT CHA
B
Reuters - 1 oy oldin

Bd Completes Acquisition Of Critical Care From Edwards Lifesciences

BRIEF-Bd Completes Acquisition Of Critical Care From Edwards Lifesciences Sept 3 (Reuters) - Becton Dickinson and Co BDX.N : BD COMPLETES ACQUISITION OF CRITICAL CARE FROM EDWARDS LIFESCIENCES Source text for Eikon: ID:nPn70KdDva Further company coverage: BDX.N
B
Reuters - 2 oy oldin

BD Names Michael Feld As President Of Life Sciences Segment

BRIEF-BD Names Michael Feld As President Of Life Sciences Segment Aug 12 (Reuters) - Becton Dickinson and Co BDX.N : BD NAMES MICHAEL FELD AS PRESIDENT OF LIFE SCIENCES SEGMENT Source text for Eikon: ID:nPn6CCzVCa Further company coverage: BDX.N ( Reuters.Briefs@thomsonreuters.com )
B
Reuters - 2 oy oldin

U.S. Apple, Centerpoint Energy, Cummins

U.S. RESEARCH ROUNDUP-Apple, Centerpoint Energy, Cummins Aug 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Apple, Centerpoint Energy and Cummins, on Friday. HIGHLIGHTS * Apple Inc AAPL.O : Wedbush raises target price to $285 from $275 * Centerpoint Energy CNP.N : JP Morgan cuts to neutral from overweight * Cummins CMI.N : Jefferies raises target price to $365 from $345 * Motorola MSI.N : JP Morgan raises target pr
A
A
B
B
I
K
M
A
B
C
A
A
A
A
C
C
L
M
Reuters - 2 oy oldin

U.S. STOCKS Spirit Airlines, Labcorp, Air Products and Chemicals

BUZZ-U.S. STOCKS ON THE MOVE-Spirit Airlines, Labcorp, Air Products and Chemicals Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main stock indexes fell over 1% on Thursday, bogged down by megacap tech and chip stocks, while small-caps bore the brunt of selling pressure as weak manufacturing data renewed concerns around a slowdown in the U.S.
B
I
J
Q
W
C
U
U
A
B
F
L
T
Reuters - 2 oy oldin

Becton falls on Q3 revenue miss

BUZZ-Becton falls on Q3 revenue miss ** Shares of medical device maker Becton Dickinson BDX.N fall 5.2% to $228.61 premarket ** Co reports Q3 revenue of $4.99 bln, missing analysts' average expectation of $5.08 bln ** Posts adj. profit of $3.50/shr vs analysts' average estimate of $3.31/shr - LSEG data ** Co raises the lower end of its full-year adj.
B
Reuters - 2 oy oldin

Becton Dickinson tops profit estimates on demand for drug-delivery devices

Becton Dickinson tops profit estimates on demand for drug-delivery devices Aug 1 (Reuters) - Becton Dickinson BDX.N reported a better-than-expected third -quarter profit on Thursday , helped by strong demand for its drug-delivery devices. Medical technology firms such as Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N are benefiting from a boost in demand as more people, especially older patients, catch up on surgeries that were put on hold during the pandemic.
A
B
Reuters - 2 oy oldin

Becton Dickinson Q3 Adjusted EPS USD 3.5 Vs. IBES Estimate USD 3.31

BRIEF-Becton Dickinson Q3 Adjusted EPS USD 3.5 Vs. IBES Estimate USD 3.31 Aug 01 (Reuters) - Becton Dickinson Q3 revenue USD 4,990 million vs. IBES estimate USD 5,076 million. Q3 EPS USD 1.68 outlook FY adjusted EPS USD 13.05-13.15
B
Reuters - 2 oy oldin

What to Watch in the Day Ahead - Thursday, August 1

What to Watch in the Day Ahead - Thursday, August 1 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Apple is expected to report a rise in third-quarter revenue, helped by higher iPad sales from new launches and strength in its services business.
A
A
B
C
I
K
V
M
B
Reuters - 2 oy oldin

Becton Dickinson and Co <BDX.N> expected to post earnings of $3.31 a share - Earnings Preview

Becton Dickinson and Co expected to post earnings of $3.31 a share - Earnings Preview Becton Dickinson and Co BDX.N , BDX is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Franklin Lakes New Jersey-based company is expected to report a 4.1% increase in revenue to $5.076 billion from $4.88 billion a year ago, according to the mean estimate from 13 analysts, based on LSEG data.
B
Reuters - 2 oy oldin

BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases

BRIEF-BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases July 25 (Reuters) - Becton Dickinson and Co BDX.N : BD: CO, QUEST DIAGNOSTICS TO DEVELOP, MANUFACTURE AND COMMERCIALIZE FLOW CYTOMETRY-BASED COMPANION DIAGNOSTICS BD: OFFERINGS WILL INCLUDE EXPLORATORY PANEL DEVELOPMENT, MANUFACTURING & DISTRIBUTION
B
Reuters - 2 oy oldin

Edwards Lifesciences falls after missing Q2 revenue estimates

BUZZ-Edwards Lifesciences falls after missing Q2 revenue estimates ** Shares of medical device maker Edwards Lifesciences EW.N fall more than 16% to $72.7 in after-hours trading ** Co misses Q2 revenue estimates, hurt by lower-than-expected demand for its artificial heart valves ** Posts revenue of $1.39 bln, missing analysts' estimates of $1.65 bl
B
Reuters - 2 oy oldin

Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices

REFILE-Edwards Lifesciences misses Q2 revenue estimates on weak demand for heart devices Corrects day in first paragraph July 24 (Reuters) - Edwards Lifesciences EW.N missed second-quarter revenue estimates on W ednesday , hurt by lower-than-expected demand for its artificial heart valves. Shares of the California-based company were down 14.3% at $74.50 after the bell.
A
B
Reuters - 2 oy oldin

BD Board Declares Dividend

BRIEF-BD Board Declares Dividend July 23 (Reuters) - Becton Dickinson and Co BDX.N : BD - DECLARED A QUARTERLY DIVIDEND OF $0.95 PER COMMON SHARE Source text for Eikon: ID:nPn2W8Q9Ca Further company coverage: BDX.N
B
Reuters - 3 oy oldin

US FDA flags shortage of Becton Dickinson's blood test tubes

US FDA flags shortage of Becton Dickinson's blood test tubes July 10 (Reuters) - The U.S. Food and Drug Administration issued an alert on Wednesday to laboratories and healthcare providers of a shortage of Becton Dickinson' BDX.N blood test tubes used in diagnosing bacterial and fungal infections. The regulator urged providers to prioritize patients at the highest risk such as those displaying signs of bloodstream infections, which can often be deadly.
B
Reuters - 3 oy oldin

BD Says Supplier Issue With Bactec Blood Culture Vials Not Expected To Have Material Financial Impact

BRIEF-BD Says Supplier Issue With Bactec Blood Culture Vials Not Expected To Have Material Financial Impact July 10 (Reuters) - Becton Dickinson and Co BDX.N : BD STATEMENT ON SUPPLIER ISSUE IMPACTING BD BACTEC™ BLOOD CULTURE VIALS BD: EXPERIENCING REDUCED AVAILABILITY OF BLOOD CULTURE VIALS FROM OUR SUPPLIER BD - SUPPLIER ISSUE IS NOT EXPECTED T
B
Reuters - 3 oy oldin

FDA Says Aware That U.S. Is Experiencing Interruptions In The Supply Of Bd Bactec Blood Culture Media Bottles Because Of Recent Supplier Issues

BRIEF-FDA Says Aware That U.S. Is Experiencing Interruptions In The Supply Of Bd Bactec Blood Culture Media Bottles Because Of Recent Supplier Issues July 10 (Reuters) - FDA: AWARE THAT U.S. IS EXPERIENCING INTERRUPTIONS IN THE SUPPLY OF BD BACTEC BLOOD CULTURE MEDIA BOTTLES BECAUSE OF RECENT SUPPLIER ISSUES FDA: DISRUPTION IN SUPPLY OF BD BACTEC BLOOD CULTURE MEDIA BOTTLES IN U.S.
B
Reuters - 3 oy oldin

U.S. Nvidia, Qualcomm, Tesla

U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla July 10 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Nvidia, Qualcomm and Tesla, on Wednesday. HIGHLIGHTS * Brighthouse Financial Inc BHF.O : Jefferies raises to buy from hold * Legalzoom.Com Inc LZ.O : JP Morgan cuts to neutral from overweight * Nvidia Corp NVDA.O : KeyBanc raises target price to $180 * Qualcomm Inc QCOM.O : KeyBanc raises target price to $225 * Tesla
A
A
A
A
A
C
G
M
M
N
P
Q
S
T
A
A
A
C
O
B
T
A
A
A
A
C
G
L
U

Shartlar

Ommabop aktivlar

Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.

Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi

Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.

Riskdan ogohlantirish: Kapitalingiz risk ostida. Kredit yordamiga ega mahsulotlar hammaga ham toʻgʻri kelmasligi mumkin. Bizning Risklardan ogohlantirishimiz bilan tanishib chiqing.